APhA 1985 CHAIRMAN CANDIDATES ARE PITTSBURGH HOSPITAL PHARMACIST NATALIE CERTO AND ALABAMA PHARMACIST/LAWYER JAMES MAIN; THREE BOARD SLOTS OPEN
APhA nominees for Chairman of the Board of Trustees for 1985 are Pittsburgh hospital pharmacist Natalie Certo, PhD, and Anniston, Alabama community pharmacist/lawyer James Main. Ballots for the assn.'s slate of nominees, which includes six candidates seeking three 1985-1987 board seats, will be mailed to APhA members in late September. The eight nominees were selected by the assn.'s Nominations Cmte. which met at APhA headquarters on Aug. 20. Both Certo and Main are members of the APhA board whose terms expire this year. Children's Hospital of Pittsburgh Pharmacy Service Director Certo has been on the assn.'s board since 1981, while Main has served as a Trustee since 1982. A magna cum laude graduate of the University of Pittsburgh Pharmacy School, Certo has been an officer of the Western Pennsylvania Society of Hospital Pharmacists and the Allegheny County Pharmaceutical Assn.She was a member of the APhA Bioavailability Panel's 1973 Practitioner Panel, the APhA Judicial Board (1976-1979), and the 1984 Presidential Search Cmte. Main is an Auburn University Pharmacy School graduate and was 1977 president of the Alabama Pharmaceutical Assn. He chaired APhA's 1980 Reference Cmte. on Public Affairs, and he was vice chairman of the 1980-81 APhA Policy Cmte. on Public Affairs. APhA's current chairman is Herbert Carlin, who will step down in January. Carlin was elected by the board last January when Maurice Bectel left the position to become interim president of the assn. after the death of Bill Apple. Board nominees are: Pair I -- MS&D's Kenneth Heimlich, PhD, and University of Wisconsin-Madison Pharmacy Dean August Lemberger, PhD; Pair II -- community pharmacists Joy Donelson, of Anchorage, Alaska, and Donald Gronewold, of Washington, Ill.; and Pair III -- San Antonio community pharmacist Timothy Vordenbaumen and Holland, Mich. hospital pharmacy director John West. Both board candidates in Pair I have Merck backgrounds: Kenneth Heimlich is MS&D's exec director of research & development, while Wisconsin Dean August Lemberger was a senior chemist for Merck & Co. before serving on the University of Wisconsin faculty from 1953 to 1969, then becoming dean of the University of Illinois Pharmacy College where he served until 1980. Heimlich was elected a Fellow of the APhA Academy of Pharmaceutical Sciences (APS) in 1976, was chairman of APS' Industrial Pharmaceutical Technology Section 1980-1981, and APS president 1982-1983. Lemberger is the current APS president and served on the APhA Judicial Board 1976-1979. Pair II board candidate Joy Donelson has been active in the Alaska Pharmaceutical Assn. since its founding in 1965, and was its president in 1974. She chaired APhA's 1979 and 1982 Reference Cmte. on Professional Affairs as well as the 1983-1984 APhA Policy Cmte. on Educational Affairs. Donald Gronewold is a past president of the Illinois Pharmacists Assn. He has been a city alderman in Washington, Ill. for eight years and is presently secty. of his county Public Health Dept. Pair III board candidate Timothy Vordenbaumen is a past president and recent treasurer of the Texas Pharmaceutical Assn., and a past chairman of the Texas assn.'s House of Delegates. He of the Michigan Pharmacy Board and a past president of the Michigan Pharmacists Assn. and Western Michigan Society of Hospital Pharmacists. West has been a member of APhA's Policy Cmtes. on Professional Affairs and Organizational Affairs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth